founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Company profile
Ticker
ANGO
Exchange
Website
CEO
James Clemmer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AngioDynamics UK Limited • RITA Medical Systems, LLC • AngioDynamics France, SARL • AngioDynamics Canada Inc. • AngioDynamics Medical Brasil Servicos de Marketing Ltda. • RadiaDyne LLC • Eximo Medical, Ltd. • AngioDynamics VA LLC ...
IRS number
113146460
ANGO stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
9 Apr 24
8-K
Results of Operations and Financial Condition
4 Apr 24
8-K
Entry into a Material Definitive Agreement
1 Apr 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Regulation FD Disclosure
11 Jan 24
10-Q
2024 Q2
Quarterly report
8 Jan 24
8-K
AngioDynamics Reports Fiscal Year 2024 Second Quarter
5 Jan 24
8-K
Departure of Directors or Certain Officers
15 Nov 23
DEFA14A
Additional proxy soliciting materials
7 Nov 23
Transcripts
ANGO
Earnings call transcript
2024 Q3
4 Apr 24
ANGO
Earnings call transcript
2024 Q2
5 Jan 24
ANGO
Earnings call transcript
2024 Q1
4 Oct 23
ANGO
Earnings call transcript
2023 Q4
12 Jul 23
ANGO
Earnings call transcript
2023 Q3
30 Mar 23
ANGO
Earnings call transcript
2023 Q2
5 Jan 23
ANGO
Earnings call transcript
2023 Q1
6 Oct 22
ANGO
Earnings call transcript
2022 Q4
12 Jul 22
ANGO
Earnings call transcript
2022 Q3
7 Apr 22
ANGO
Earnings call transcript
2022 Q2
6 Jan 22
Latest ownership filings
4
James C Clemmer
8 Apr 24
4
Stephen A Trowbridge
4 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
9 Feb 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
23 Jan 24
SC 13G/A
BlackRock Inc.
23 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
SC 13G/A
BlackRock Inc.
6 Oct 23
4/A
Stephen A Trowbridge
21 Sep 23
4/A
Dave Helsel
21 Sep 23
Financial summary
Quarter (USD) | Nov 23 | Aug 23 | May 23 | Feb 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | May 23 | May 22 | May 21 | May 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.90 mm | 60.90 mm | 60.90 mm | 60.90 mm | 60.90 mm | 60.90 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.37 mm | 801.58 k | (no burn) | 275.75 k |
Cash used (since last report) | n/a | n/a | 21.09 mm | 3.87 mm | n/a | 1.33 mm |
Cash remaining | n/a | n/a | 39.80 mm | 57.03 mm | n/a | 59.57 mm |
Runway (months of cash) | n/a | n/a | 9.1 | 71.1 | n/a | 216.0 |
Institutional ownership, Q3 2023
88.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 152 |
Opened positions | 27 |
Closed positions | 29 |
Increased positions | 68 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 257.29 bn |
Total shares | 35.26 mm |
Total puts | 0.00 |
Total calls | 700.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.16 mm | $30.42 bn |
Millennium Management | 2.70 mm | $19.72 bn |
Vanguard | 2.13 mm | $15.59 bn |
Systematic Financial Management | 1.90 mm | $13.89 bn |
Dimensional Fund Advisors | 1.67 mm | $12.21 bn |
MS Morgan Stanley | 1.55 mm | $11.34 bn |
STT State Street | 1.27 mm | $9.25 bn |
Assenagon Asset Management | 1.05 mm | $7.70 bn |
Citadel Advisors | 1.01 mm | $7.38 bn |
Geode Capital Management | 847.30 k | $6.19 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | James C Clemmer | Common Stock | Buy | Acquire P | No | No | 6.7 | 10,000 | 67.00 k | 539,066 |
29 Feb 24 | Trowbridge Stephen A | Common Stock | Grant | Acquire A | No | No | 4.67 | 1,927 | 9.00 k | 128,901 |
21 Jul 23 | Trowbridge Stephen A | Common Stock | Payment of exercise | Dispose F | No | No | 8.65 | 667 | 5.77 k | 114,595 |
21 Jul 23 | James C Clemmer | Common Stock | Payment of exercise | Dispose F | No | No | 8.65 | 3,372 | 29.17 k | 529,066 |
21 Jul 23 | Helsel Dave | Common Stock | Payment of exercise | Dispose F | No | No | 8.65 | 365 | 3.16 k | 28,289 |
20 Jul 23 | Trowbridge Stephen A | Common Stock | Payment of exercise | Dispose F | No | No | 8.74 | 717 | 6.27 k | 115,262 |
20 Jul 23 | James C Clemmer | Common Stock | Payment of exercise | Dispose F | No | No | 8.74 | 2,982 | 26.06 k | 532,438 |
20 Jul 23 | Helsel Dave | Common Stock | Payment of exercise | Dispose F | No | No | 8.74 | 332 | 2.90 k | 28,654 |
News
Insiders Buying Zumiez And 3 Other Stocks
9 Apr 24
Oppenheimer Upgrades AngioDynamics to Outperform, Announces $12 Price Target
5 Apr 24
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
4 Apr 24
AngioDynamics Q3 Adjusted EPS $(0.16) Misses $(0.13) Estimate, Sales $75.18M Miss $75.73M Estimate
4 Apr 24
AngioDynamics Secures 510(k) Clearance For AlphaVac F1885 System In Treatment Of Pulmonary Embolism
4 Apr 24
Press releases
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
4 Apr 24
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
4 Apr 24
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
1 Apr 24
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
6 Mar 24